SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences gains on reporting decent Q1 numbers

10 Aug 2011 Evaluate

Jubilant Life Sciences is currently trading at Rs. 202.90, up by 10.15 points or 5.27% from its previous closing of Rs. 192.75 on the BSE.

The scrip opened at Rs. 200.00 and has touched a high and low of Rs. 205.00 and Rs. 196.00 respectively.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 353.04 on 24-Aug-2010 and a 52 week low of Rs. 148.45 on 28-Mar-2011.

Last one week high and low of the scrip stood at Rs. 211.60 and Rs. 185.00 respectively. The current market cap of the company is Rs. 3231.00 crore.

The promoters holding in the company stood at 47.18 % while Institutions and Non-Institutions held 31.97 % and 20.85 % respectively.

The company’s consolidated net profit rose 52.92% to Rs 77.12 crore for the first quarter ended June 30, 2011, against Rs 50.43 crore in the same period previous fiscal. Total income rose to Rs 948.48 crore for the quarter ended June 30, 2011 up by 15.86% compared with Rs 818.61 crore in the same period previous financial year.

The company’s net profit declined by 20.50% to Rs 53.89 crore for the first quarter ended June 30, 2011, against Rs 67.79 crore in the same period previous fiscal. Total income rose to Rs 618.75 crore for the quarter ended June 30, 2011, up by 18.84% compared with Rs 520.64 crore in the same period previous financial year.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×